The estimated Net Worth of Ventures I Llcversant Ventu... is at least $15.4 Million dollars as of 31 May 2016. Ventures Ventu owns over 34,058 units of Glaukos stock worth over $13,729,073 and over the last 8 years Ventures sold GKOS stock worth over $1,633,422.
Ventures has made over 2 trades of the Glaukos stock since 2016, according to the Form 4 filled with the SEC. Most recently Ventures sold 34,058 units of GKOS stock worth $816,711 on 31 May 2016.
The largest trade Ventures's ever made was selling 34,058 units of Glaukos stock on 31 May 2016 worth over $816,711. On average, Ventures trades about 34,058 units every 0 days since 2016. As of 31 May 2016 Ventures still owns at least 109,395 units of Glaukos stock.
You can see the complete history of Ventures Ventu stock trades at the bottom of the page.
Ventures's mailing address filed with the SEC is 1 Sansome St # 2000, San Francisco, CA 94104, USA.
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman, and Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: